Search Results
Sep 27, 2025, 10:36 ET JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit
investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to
More news about: THE ROSEN LAW FIRM, P. A.
Sep 25, 2025, 16:46 ET Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR
JSPR ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of JSPR during the class period listed
More news about: DJS Law Group LLP
Sep 25, 2025, 12:00 ET JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
recognized law firm, notifies investors that a class action lawsuit has been filed against Jasper Therapeutics, Inc. ("Jasper" or "the Company") (NASDAQ: JSPR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged
More news about: Bronstein, Gewirtz & Grossman, LLC
Sep 24, 2025, 20:34 ET Jasper Therapeutics, Inc. Class Action Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the JSPR Class Action Lawsuit
stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Jasper Therapeutics, Inc. (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025. Jasper, a clinical-stage biotechnology
More news about: Robbins LLP
Sep 24, 2025, 10:40 ET SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
LLP, a leading national securities law firm, is investigating potential claims against Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR) and reminds investors of the November 18, 2025 deadline to seek the role of lead plaintiff in a federal securities
More news about: Faruqi & Faruqi, LLP
Sep 23, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR) and certain officers. The class action, filed in the United States District Court for the Northern District of
More news about: Pomerantz LLP
Sep 22, 2025, 16:09 ET JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit
investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"). A
More news about: THE ROSEN LAW FIRM, P. A.
Sep 20, 2025, 08:00 ET Do you own shares of KBR? Robbins LLP Informs Investors of the Jasper Therapeutics, Inc. Class Action Lawsuit
stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Jasper Therapeutics, Inc. (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025. Jasper, a clinical-stage biotechnology
More news about: Robbins LLP
Aug 16, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Aug 11, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Aug 06, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jul 31, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jul 27, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jul 22, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jul 17, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jul 12, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jun 18, 2025, 08:15 ET Freehold Capital Management Enters Q3 with New Projects, Developments and Team
More news about: Freehold Capital Management